×
About 3,405 results

ALLMedicine™ Autoimmune Hepatitis Center

Research & Reviews  1,230 results

Tacrolimus-Induced Neurotoxicity in Early Post-Liver Transplant Saudi Patients: Inciden...
https://doi.org/10.12659/AOT.935938
Annals of Transplantation; Alissa DA, Alkortas D et. al.

May 18th, 2022 - BACKGROUND Tacrolimus is a calcineurin inhibitor (CNI) commonly used as an immunosuppressant to prevent the rejection of organ transplants. After liver transplantation, it can cause early neurological complications, known as early calcineurin inhi...

Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role ...
https://doi.org/10.1002/hep.32572
Hepatology (Baltimore, Md.); Efe C, Kulkarni AV et. al.

May 15th, 2022 - A few case reports of autoimmune hepatitis like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury followi...

Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematos...
https://doi.org/10.1111/1756-185X.14331
International Journal of Rheumatic Diseases; Gomathy S, Panigrahi B et. al.

May 11th, 2022 - Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating central nervous system illness encountered in the setting of immunosuppressive conditions like human immunodeficiency virus / acquired immunodeficiency syndrome, autoimmune d...

The intestinal and biliary microbiome in autoimmune liver disease-current evidence and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088151
Seminars in Immunopathology; Liwinski T, Heinemann M et. al.

May 11th, 2022 - Autoimmune liver diseases are a group of immune-mediated liver diseases with three distinct entities, including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. The interplay of genetic and environmental facto...

see more →

Guidelines  5 results

Best practice guidelines for France regarding the diagnosis and management of autoimmun...
https://doi.org/10.1016/j.clinre.2022.101871
Clinics and Research in Hepatology and Gastroenterology; Duclos-Vallée JC, Debray D et. al.

Feb 3rd, 2022 - Best practice guidelines for France regarding the diagnosis and management of autoimmune hepatitis.|2022|Duclos-Vallée JC,Debray D,De Martin E,Beux EL,Louvet A,|

Non-invasive diagnosis and follow-up of autoimmune hepatitis.
https://doi.org/10.1016/j.clinre.2021.101772
Clinics and Research in Hepatology and Gastroenterology; Lemoinne S, Heurgue A et. al.

Aug 1st, 2021 - Autoimmune hepatitis (AIH) is a liver disease characterised by necrotico-inflammatory lesions of hepatocytes, the presence of specific autoantibodies and response to corticosteroid treatment. AIH must be considered in any patient with acute or chr...

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice ...
https://doi.org/10.1002/hep.31065
Hepatology (Baltimore, Md.); Mack CL, Adams D et. al.

Dec 22nd, 2019 - Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.|2019|Mack CL,Adams D,Assis DN,Kerkar N,Manns MP,|diagnosis,drug therapy,

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Diagnosis and management of autoimmune hepatitis.
https://doi.org/10.1002/hep.23584
Hepatology (Baltimore, Md.); Manns MP, Czaja AJ et. al.

Jun 1st, 2010 - Diagnosis and management of autoimmune hepatitis.|2010|Manns MP,Czaja AJ,Gorham JD,Krawitt EL,Mieli-Vergani G,|blood,diagnosis,drug therapy,immunology,pathology,

see more →

Drugs  10 results see all →

Clinicaltrials.gov  17 results

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
https://clinicaltrials.gov/ct2/show/NCT05335603

Apr 19th, 2022 - Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatit...

The Pathogenesis of Depression - Possible Autoimmune Mechanisms
https://clinicaltrials.gov/ct2/show/NCT05293899

Mar 24th, 2022 - It has long been claimed that depression, and other psychiatric illness, might be a manifestation of immune dysregulation involving the Central nervous system. Depression is associated with a significantly increased risk of autoimmune disease comp...

Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy
https://clinicaltrials.gov/ct2/show/NCT05221411

Feb 3rd, 2022 - Rationale: The combination of azathioprine and prednisone is the first-line treatment for autoimmune hepatitis (AIH), a chronic inflammatory disease of the liver. Complete biochemical remission (CR) is the first treatment goal in autoimmune hepati...

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
https://clinicaltrials.gov/ct2/show/NCT04861571

Sep 28th, 2021 - Study design: The investigators plan to perform a non-controlled, non-randomized, open-label, pilot clinical trial to evaluate the effect of an 8-week VLCD intervention on NAFLD. The main variable of this study is the magnitude of liver steatosis ...

Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives
https://clinicaltrials.gov/ct2/show/NCT04281082

Sep 2nd, 2021 - Introduction: ICP is commolnly manifested in the 2nd and especially in the 3rd trimester of pregnancy. Pathogenesis of ICP is multifactorial implicating genetic, environmental and hormonologic factors. Prevalence of ICP varies. In certain populati...

see more →

News  93 results

Herbal Products for IBS; Liver Transplant, Diabetes, and Cancer; IBD Work Impairment
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/97151

Feb 11th, 2022 - A case-control study revealed which patients were more likely to use herbal products for irritable bowel syndrome. (BMC Gastroenterology) Diabetes following a liver transplant was linked to cancer risk, a study from Italy found. (Annals of Hepatol...

Immune-Mediated Diseases Tied to Risk of Cancer
https://www.medscape.com/viewarticle/964508

Dec 10th, 2021 - NEW YORK (Reuters Health) - Immune-mediated diseases were associated with an increased risk of local and systemic cancers, as well as total cancers, in a large cohort study, supporting the role of local and systemic immunoregulation in the develop...

The Best Liver Tests in Primary Care
https://www.medscape.com/viewarticle/961292

Nov 30th, 2021 - This transcript has been edited for clarity. Matthew F. Watto, MD: Welcome back to The Curbsiders. I'm Dr Matthew Watto, here with my great friend, Dr Paul Nelson Williams. Paul, what are we going to talk about today? Paul N. Williams, MD: In thes...

As FDA Review Approaches, Finn Reflects on the Utility of Pembrolizumab, Nivolumab in HCC
https://www.onclive.com/view/as-fda-review-approaches-finn-reflects-on-the-utility-of-pembrolizumab-nivolumab-in-hcc

Oct 6th, 2021 - Pembrolizumab (Keytruda) and nivolumab (Opdivo) represent valuable second-line treatment options for patients with hepatocellular carcinoma (HCC), despite not having met the end points of the confirmatory KEYNOTE-240 and CheckMate-459 trials, resp...

Frontline Nivolumab Plus Chemo Shows Practice-Changing Potential in GI Cancers
https://www.onclive.com/view/frontline-nivolumab-plus-chemo-shows-practice-changing-potential-in-gi-cancers

Oct 6th, 2021 - The combination of nivolumab (Opdivo) plus standard-of-care chemotherapy has demonstrated groundbreaking efficacy and tolerability in patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal aden...

see more →

Patient Education  7 results see all →